1Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
2Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
Copyright © 2016 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | Patients | No. of stents | Stent duration, mo | No. of ERC | F/U duration, mo | Resolution of AS, n (%) | Recurrence of AS, n (%) | Complications |
---|---|---|---|---|---|---|---|---|
Rerknimitr et al. (2002) [19] | 43 | 2.8 | 15.8 | 3.8 | 56.5 | 43/43 (100) | 0/43 (0) | Stent migration, fistula, bleeding (no. of cases not listed) |
Alazmi et al. (2006) [20] | 148 | 3 | 2.5 | 3 | 32 | 131/148 (89) | 24/131 (18) | - |
Pasha et al. (2007) [21] | 25 | 2 | 4.65 | 3.5 | 21.5 | 22/25 (88) | 2/22 (9) | 5/105 ERC (4.8%): pancreatitis, fever, stent migration, hypoxia |
Holt et al. (2007) [17] | 53 | 11 | 3 | 18 | 34/53 (63) | 1/34 (3) | 11/53 Patients (20%): pancreatitis, minor complications (not listed) | |
Morelli et al. (2008) [15] | 38 | 2.5 | 3.5 | 3.45 | 12 | 33/38 (87) | 5/33 (15) | 2/38 Patients (5%): cholangitis |
Tabibian et al. (2010) [18] | 69 | 2.5 | 15 | 4.2 | 11 | 65/69 (94) | 2/65 (3) | 4/268 ERC (1.5%): pancreatitis, bacteremia |
Albert et al. (2013) [22] | 47 | 2.5 | 28 | 4.2 | 36 | 26/47 (63) | 15/41 (37) | 32/198 ERC (16%): cholangitis, pancreatitis, bleeding, perforation |
Poley et al. (2013) [23] | 31 | 4 | - | 5 | 28 | 25/31 (80) | - | 21/31 Patients (67%): cholangitis, pancreatitis, cholestasis |
Study | Patients | Stent duration, mo | F/U duration, mo | Resolution of AS, n (%) | Recurrence of AS, n (%) | Complications |
---|---|---|---|---|---|---|
Traina et al. (2009) [33] | 16 | 2 | 10 | 13/16 (81) | 1/13 (7) | 7/16 Patients (44%): stent migration (38%), pancreatitis |
Poley et al. (2012) [36] | 23 | 5.5 | 15.5 | 14/23 (61) | - | 6/23 Patients (26%): stent migration (4%), cholangitis, cholecystitis |
Tarantino et al. (2012) [35] | 39 (group 1)a) | 2 | 22.1 | 28/39 (72) | 4/28 (14) | 13/39 Patients (33%): stent migration |
15 (group 2)b) | 14.4 | 8/15 (53) | 2/8 (25) | 7/15 Patients (46%): stent migration | ||
Sauer et al. (2012) [37] | 19 | 2-3 | 12 | 6/8c) (75) | 1/6 (17) | 8/19 Patients (42%): stent migration, occlusion, stricture |
Kahaleh et al. (2013) [34] | 35 | 3.1 | - | 19/31 (61) | - | 36% Stent migration |
Study | Patients | No. of stents | Stent duration, mo | No. of ERC | F/U duration, mo | Resolution of AS, n (%) | Recurrence of AS, n (%) | Complications |
---|---|---|---|---|---|---|---|---|
Rerknimitr et al. (2002) [19] | 43 | 2.8 | 15.8 | 3.8 | 56.5 | 43/43 (100) | 0/43 (0) | Stent migration, fistula, bleeding (no. of cases not listed) |
Alazmi et al. (2006) [20] | 148 | 3 | 2.5 | 3 | 32 | 131/148 (89) | 24/131 (18) | - |
Pasha et al. (2007) [21] | 25 | 2 | 4.65 | 3.5 | 21.5 | 22/25 (88) | 2/22 (9) | 5/105 ERC (4.8%): pancreatitis, fever, stent migration, hypoxia |
Holt et al. (2007) [17] | 53 | 11 | 3 | 18 | 34/53 (63) | 1/34 (3) | 11/53 Patients (20%): pancreatitis, minor complications (not listed) | |
Morelli et al. (2008) [15] | 38 | 2.5 | 3.5 | 3.45 | 12 | 33/38 (87) | 5/33 (15) | 2/38 Patients (5%): cholangitis |
Tabibian et al. (2010) [18] | 69 | 2.5 | 15 | 4.2 | 11 | 65/69 (94) | 2/65 (3) | 4/268 ERC (1.5%): pancreatitis, bacteremia |
Albert et al. (2013) [22] | 47 | 2.5 | 28 | 4.2 | 36 | 26/47 (63) | 15/41 (37) | 32/198 ERC (16%): cholangitis, pancreatitis, bleeding, perforation |
Poley et al. (2013) [23] | 31 | 4 | - | 5 | 28 | 25/31 (80) | - | 21/31 Patients (67%): cholangitis, pancreatitis, cholestasis |
Study | Patients | Stent duration, mo | F/U duration, mo | Resolution of AS, n (%) | Recurrence of AS, n (%) | Complications |
---|---|---|---|---|---|---|
Traina et al. (2009) [33] | 16 | 2 | 10 | 13/16 (81) | 1/13 (7) | 7/16 Patients (44%): stent migration (38%), pancreatitis |
Poley et al. (2012) [36] | 23 | 5.5 | 15.5 | 14/23 (61) | - | 6/23 Patients (26%): stent migration (4%), cholangitis, cholecystitis |
Tarantino et al. (2012) [35] | 39 (group 1) |
2 | 22.1 | 28/39 (72) | 4/28 (14) | 13/39 Patients (33%): stent migration |
15 (group 2) |
14.4 | 8/15 (53) | 2/8 (25) | 7/15 Patients (46%): stent migration | ||
Sauer et al. (2012) [37] | 19 | 2-3 | 12 | 6/8 |
1/6 (17) | 8/19 Patients (42%): stent migration, occlusion, stricture |
Kahaleh et al. (2013) [34] | 35 | 3.1 | - | 19/31 (61) | - | 36% Stent migration |
Variable | Multiple plastic stent group | Full-covered metal stent group | p-value |
---|---|---|---|
Stent duration, mo | 10.01±8.30 | 2.87±1.22 | 0.000 |
Resolution | 369 (87.2) | 55 (61.8) | 0.003 |
Recurrence | 49 (13.3) | 8 (14.5) | 0.797 |
Complication | 75 (29.0) | 54 (36.7) | 0.065 |
ERC, endoscopic retrograde cholangiography; F/U, follow-up; AS, anastomotic stricture.
F/U, follow-up; AS, anastomotic stricture. Group 1: self-expandable metal stent (SEMS) insertion after treatment failure of conventional plastic stent insertion; Group 2: SEMS insertion at first line therapy of AS; Only eight patients diagnosed AS after liver transplantation.
Values are presented as mean±SD or number (%).